About the Report
- The checkpoint space is continuing to grow with a 48% average annual growth rate in checkpoint-related trials between 2014 to 2021, with thousands of trials being initiated in 2022 so far.
- The turbulent global market conditions are presenting lots of business opportunities, with eight acquisitions among checkpoint developers in H1 2022.
- Following on from previous activity, H1 of 2022 has seen high investment in the space, therefore, we can expect to see an increase in the number of novel therapeutics emerging and entering the clinic.
- Download the Trial Landscape 2022 analysis for a detailed report of current updates.
Find out more
The data from this mid-year landscape review is available on the Beacon Checkpoint platform.
Speak with our expert Team
Our dedicated team is on hand to showcase how Beacon can help you find the answers to your checkpoint questions.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
